Literature DB >> 31964510

The Ocular Surface Frailty Index as a Predictor of Ocular Surface Symptom Onset after Cataract Surgery.

Edoardo Villani1, Luca Marelli2, Francesco Bonsignore2, Stefano Lucentini2, Saverio Luccarelli2, Matteo Sacchi2, Massimiliano Serafino2, Paolo Nucci2.   

Abstract

PURPOSE: The identification of healthy persons more susceptible to dry eye (DED) symptoms developing after surgery remains an unmet need. We performed this study to build a new Ocular Surface Frailty Index (OSFI) and assess its predictive value for DED symptom onset after cataract surgery.
DESIGN: Single-center, observational, longitudinal study. PARTICIPANTS: We screened 405 consecutive patients scheduled for phacoemulsification for age-related cataract. Two hundred eighty-four eyes of 284 patients without preoperative DED symptoms who underwent uneventful cataract surgery were included in the analysis.
METHODS: We built a tool to assess ocular surface frailty. Starting from a preliminary list of 19 potential items, the final OSFI, including 10 deficits in ocular surface health, factors potentially able to affect it, or both, was developed by a stepwise approach. Preoperative OSFI results were calculated for each enrolled patient and diagnostic tests for DED were performed at the screening visit and 1 week, 1 month, and 3 months after surgery. We evaluated the ability of OSFI to predict the presence of DED symptoms at 1 month or 3 months after surgery, or both. MAIN OUTCOME MEASURES: The rate of ocular surface symptoms at 1 month or 3 months after surgery, or both.
RESULTS: Our patients' OSFI scores ranged from 0 to 0.666, with a median value of 0.200. The percentage of patients with postsurgical ocular surface symptoms was 17%. Using an OSFI cutoff of 0.300, we identified a small group (19% of the asymptomatic patients) with frail ocular surfaces who showed a significantly higher risk of postsurgical DED symptoms develop (50.0% vs. 9.6%; P < 0.001, chi-square test). Logistic regression analysis showed that OSFI results of 0.3 or more (but not age, gender, or any preoperative sign) was a good predictor of ocular surface symptom onset (odds ratio, 9.45; 95% confidence interval, 4.74-18.82). Regression remained significant when performed on 200 bootstrapped samples.
CONCLUSIONS: The OSFI can be calculated easily and quickly using noninvasive and low-tech procedures, and it proved to be predictive of postoperative DED symptoms onset. This novel tool may allow cataract surgeons to perform a useful preoperative personalized risk assessment.
Copyright © 2020 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31964510     DOI: 10.1016/j.ophtha.2019.12.012

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  4 in total

Review 1.  Prevalence and Characteristics of Dry Eye Disease After Cataract Surgery: A Systematic Review and Meta-Analysis.

Authors:  Maria Miura; Takenori Inomata; Masahiro Nakamura; Jaemyoung Sung; Ken Nagino; Akie Midorikawa-Inomata; Jun Zhu; Keiichi Fujimoto; Yuichi Okumura; Kenta Fujio; Kunihiko Hirosawa; Yasutsugu Akasaki; Mizu Kuwahara; Atsuko Eguchi; Hurramhon Shokirova; Akira Murakami
Journal:  Ophthalmol Ther       Date:  2022-05-09

2.  Evaluation of the effect of gentamicin in surgical perfusion solution on cataract postoperative endophthalmitis.

Authors:  Wenjiang Ma; Guanghua Hou; Junfang Wang; Ting Liu; Fang Tian
Journal:  BMC Ophthalmol       Date:  2022-10-23       Impact factor: 2.086

3.  Presbyopia: An outstanding and global opportunity for early detection of pre-frailty and frailty states.

Authors:  Almudena Crooke; Irene Martínez-Alberquilla; David Madrid-Costa; Javier Ruiz-Alcocer
Journal:  Front Med (Lausanne)       Date:  2022-10-04

4.  Clinical efficacy of diquafosol sodium 3% versus hyaluronic acid 0.1% in patients with dry eye disease after cataract surgery: a protocol for a single-centre, randomised controlled trial.

Authors:  Maria Miura; Takenori Inomata; Shuko Nojiri; Jaemyoung Sung; Masashi Nagao; Jun Shimazaki; Akie Midorikawa-Inomata; Yuichi Okumura; Kenta Fujio; Yasutsugu Akasaki; Mizu Kuwahara; Tianxiang Huang; Masahiro Nakamura; Masao Iwagami; Kunihiko Hirosawa; Keiichi Fujimoto; Akira Murakami
Journal:  BMJ Open       Date:  2022-01-31       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.